Review argues multi-cannabinoid combinations may treat Alzheimer's more effectively than CBD or THC alone

CBD reversed and prevented cognitive deficits in AD rodent models through anti-inflammatory, antioxidant, and neuroprotective mechanisms. Low-dose THC improved cognition in aging mice. The "entourage effect" suggests that multi-cannabinoid formulations (whole plant extracts or specific CBD:THC ratios) may be more efficacious than cannabinoid isolates for AD therapy.

Narrative review of preclinical and early clinical evidence for cannabinoid-based Alzheimer's treatments, with emphasis on multi-cannabinoid strategies and the entourage effect.

With no disease-modifying treatments for Alzheimer's, the ability of cannabinoids to target multiple pathological features (amyloid plaques, neurofibrillary tangles, neuroinflammation, oxidative stress) simultaneously is compelling.

Alzheimer's involves multiple overlapping pathologies, making multi-target treatment strategies theoretically attractive. Cannabinoids' ability to address inflammation, oxidative stress, and neurodegeneration simultaneously is unique among potential therapeutics.

Almost entirely preclinical evidence. No clinical trials of multi-cannabinoid strategies for AD. Optimal doses and ratios unknown. THC's psychoactive effects could be problematic for elderly patients. Animal models imperfectly replicate human AD.